Progenitor cells of mesodermal lineage
AssigneeCell Therapy Limited
InventorsThomas Averell Houze, Martin John Evans, Ajan Trevor Reginald, Ina Laura Pieper
Life of this patent
Estimating the term…
Abstract
The invention relates to progenitor cells of mesodermal lineage and their use in therapy.
Claims38
A progenitor cell of mesodermal lineage, wherein the cell (a) expresses detectable levels of CD29, CD44, CD73, CD90, CD105 and CD271 and (b) does not express detectable levels of CD14, CD34 and CD45.
A progenitor cell according to any one of the preceding claims, wherein the cell is capable of having anti-inflammatory effects in a damaged tissue in a patient.
A progenitor cell according to any one of the preceding claims, wherein the cell expresses detectable levels of one or more of (i) insulin-like growth factor-1 (IGF-1), (ii) IGF-1 receptor;
- (iii) C-C chemokine receptor type 1 (CCR1), (iv) stromal cell-derived factor-1 (SDF-1), (v) hypoxia-inducible factor-1 alpha (HIF-1 alpha), (vi) Akt1 and (vii) hepatocyte growth factor (HGF) and/or granulocyte colony-stimulating factor (G-CSF).
A progenitor cell according to any one of the preceding claims, wherein the cell expresses detectable levels of one or more of (i) vascular endothelial growth factor (VEGF), (ii) transforming growth factor beta (TGF-beta), (iii) insulin-like growth factor-1 (IGF-1), (iv) fibroblast growth factor (FGF), (v) tumour necrosis factor alpha (TNF-alpha), (vi) interferon gamma (IFN-gamma) and (vii) interleukin-1 alpha (IL-1 alpha)
A progenitor cell according to any one of the preceding claims, wherein the cell is autologous.
Dependencies are inferred from the claim text.